José Luís Carneiro considerado o melhor líder para o PS

[pedro200]

Interessante:

http://www.innoplus.it/public/default.a ... torMenu=18

A generex em Milão (Itália)....

[pedro200]

Boas Pedro

Onde consukltas os ultimos negocios das acções em OTCBB e PK.

Obrigado

Cumps

Kuby

os últimos negocios da Generex consulto no site:
http://www.nasdaq.com/aspx/nasdaqlastsa ... ected=GNBT

www.nasdaq.com (seleccionas a opção real-time quotes)

Cumprimentos

[kuby]

Boas Pedro

Onde consukltas os ultimos negocios das acções em OTCBB e PK.

Obrigado

Cumps

Kuby

[pedro200]

Bom Fecho!

16:00:00 $ .40 100,000
16:00:00 $ .40 100,000
15:59:56 $ .3946 100
15:59:56 $ .3946 100
15:59:56 $ .3946 100

mas a estrela do dia foi a DNDN....

[pedro200]

Gostei deste artigo acabado de ser publicado.

http://seekingalpha.com/article/217935- ... urce=yahoo

ia colocar agora mesmo esse artigo!

a generex tem um fantástico pipeline!


"If it succeeds, Generex may well be one of the large biotechs of the future." - Thomas Barnard

[pedro200]

http://finance.yahoo.com/news/Generex-B ... l?x=0&.v=1


WORCESTER, Mass., Aug. 2, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has created a scientific advisory board in an effort to further its drug development programs, specifically in the areas of oncology and metabolic diseases. Management of Generex has been in late stage talks with a number of key industry leaders in the pharmaceutical and biotechnology industry to assist the Company in positioning its more later stage drug delivery and vaccine programs for commercialization and to further the advancement of its rich pipeline of metabolic and oncology related programs.



"We believe we are at the cusp of several significant advancements toward the commercial realization for the sciences we have been developing at our Company since our inception. We are confident that now is the time to bring a number of industry leaders together to help to guide our Company down the path to commercial success," stated Anna Gluskin, the Company's President & Chief Executive Officer. "We have been in discussions with some current industry leaders in oncology and metabolic diseases and we look forward to bringing in a group of professionals capable of providing us with the additional experience and insight to help us deliver on the promise of our strong pipeline of life improving drug programs."

[AC Investor Blog]

Gostei deste artigo acabado de ser publicado.

http://seekingalpha.com/article/217935- ... urce=yahoo

[nk667]

Update:

http://pipelinereview.blogspot.com/2010 ... pdate.html

[nk667]

Bem,

Saltou-me um alerta nos últimos 2 minutos no screen do meu computador desta menina, e não é que disparou 7% num ápice......

Cheguei Primeiro!
Também reparei no salto!

(rumores dizem que o reserve split foi recusado!) - atenção informação não confirmada pela generex!
Um Abraço AC!

Pois parece que nao vai acontecer

Foi divulgada agora a noticia:

http://finance.yahoo.com/news/Generex-A ... l?x=0&.v=1

Abraço

[pedro200]

Bem,

Saltou-me um alerta nos últimos 2 minutos no screen do meu computador desta menina, e não é que disparou 7% num ápice......

Cheguei Primeiro!
Também reparei no salto!

(rumores dizem que o reserve split foi recusado!) - atenção informação não confirmada pela generex!
Um Abraço AC!

[AC Investor Blog]

Bem,

Saltou-me um alerta nos últimos 2 minutos no screen do meu computador desta menina, e não é que disparou 7% num ápice......

[pedro200]

NASDAQ Last Sale (NLS)
for the last five trades
NLS
Time (ET) NLS
Price NLS
Share Volume
16:00:01 $ .40 150,000
15:59:59 $ .40 300
15:59:56 $ .40 4,250
15:59:56 $ .40 750
15:59:50 $ .40 1,100


http://www.nasdaq.com/aspx/nasdaqlastsa ... ected=GNBT

[pedro200]

deve sair a aprovação do reserve split (3 para 1 é a minha aposta)

O R/S terá que ser feito no mínimo de 10 para 1.
Nao há absolutamente nenhum sentido em fazer um R/S de r para 1 para a cotacao ficar a 1US$. Para que ? Para fazer outro de seguida ? LOLADA.

Errado! No máximo 10 para 1. No mínimo 3 para 1.

Errado !
O R/S pode ser ao valor que bem se entender, com o intuito da cotacao estar mais longe possivel de 1.00 US$ e com a cotacao actual NUNCA será escolhido 3 para 1 !

Estás errado!

Vê:
FOR the approval of an amendment to our Restated Certificate of Incorporation (i) to effect a reverse stock split of our common stock, at an exchange ratio of not less than 1-for-3 and not more than 1-for 10 at any time prior to July 27, 2011 (the ratio and timing of which will be subject to the discretion of the Board of Directors), and (ii) following the reverse stock split, to maintain the authorized shares of common stock at 750,000,000.


... ou seja: no mínimo vai ser 3 para 1, no máximo 10 para 1.
Limitei-me a publicar a informação divulgada pela gnbt.

Um abraço a todos! Vou de férias!

[MatildeSerrano]

deve sair a aprovação do reserve split (3 para 1 é a minha aposta)

O R/S terá que ser feito no mínimo de 10 para 1.
Nao há absolutamente nenhum sentido em fazer um R/S de r para 1 para a cotacao ficar a 1US$. Para que ? Para fazer outro de seguida ? LOLADA.

Errado! No máximo 10 para 1. No mínimo 3 para 1.

Errado !
O R/S pode ser ao valor que bem se entender, com o intuito da cotacao estar mais longe possivel de 1.00 US$ e com a cotacao actual NUNCA será escolhido 3 para 1 !

[pedro200]

deve sair a aprovação do reserve split (3 para 1 é a minha aposta)

O R/S terá que ser feito no mínimo de 10 para 1.
Nao há absolutamente nenhum sentido em fazer um R/S de r para 1 para a cotacao ficar a 1US$. Para que ? Para fazer outro de seguida ? LOLADA.

Errado! No máximo 10 para 1. No mínimo 3 para 1.

[MatildeSerrano]

deve sair a aprovação do reserve split (3 para 1 é a minha aposta)

O R/S terá que ser feito no mínimo de 10 para 1.
Nao há absolutamente nenhum sentido em fazer um R/S de r para 1 para a cotacao ficar a 1US$. Para que ? Para fazer outro de seguida ? LOLADA.

[pedro200]

"July 28, 2010 9:35 AM EDT

Generex Biotechnology Corporation (Nasdaq: GNBT) today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product. These early results suggest that, should the current trend be maintained through the early 2011 completion date of the treatment phase of all enrolled subjects, the use of Generex Oral-lyn™ will support a non-inferiority claim relative to the standard-of-care injectable insulin. This position will be reviewed following a formal interim analysis after the 90-day results for all subjects become available.

It is gratifying for the Company to see a continuum of positive trends. Initial trending outcomes revealed that insulin resistance was not observed for subjects using Generex Oral-lyn™ and that subjects using Generex Oral-lyn™ demonstrated, on average, no weight gain and an actual decrease in Body Mass Index (BMI). This compared favorably to subjects using injectable insulin that have, on average, gained weight and experienced an increase in BMI. In addition, it was previously reported that when comparing hypoglycemic events, subjects using Generex Oral-lyn™ were observed to have a better Adverse Event profile than subjects using injectable insulin. These previous findings along with current trends of non-inferiority using recently collected information and extrapolations clearly positions this study favorably.

A basic understanding of some clinical trial and statistical terms:

Double-blind, randomized trials are best, especially in phase 3. Patients have been randomly assigned to receive placebo (or an alternative drug) or the drug under investigation, and neither the patients nor the doctors know who is getting what (that's the "blind" part), and neither does the company. This means that trial results should be come from just the action of the drug and not "massaged" by researchers. Showing that a drug is "non-inferior" means it's "at least as good as," but for judging potential sales, "superior" can be better. Finally, to be successful, the results have to be "statistically significant." That is, the probability that the results are due to chance has to be really small. Smaller is better, so a "p ≤ 0.005" (0.5% probability that the result is a fluke) is better than "p ≤ 0.01" (1% probability that the result is a fluke).


Só mais uma informação: o sucesso(caso os resultados sejam positivos) na fase III de um medicamento pode fazer milagres à cotação. Alguém se lembra do que aconteceu à HGSI no dia 20 de Julho de 2009 (Successful phase 3 trial of lupus treatment Benlysta) Em Março de 2009 valia 50 centimos. Hoje, um ano e 4 meses depois, vale 25)

[pedro200]

Video - Generex - Oral lyn!
http://vimeo.com/5094769

[pedro200]

"July 28, 2010 9:35 AM EDT

Generex Biotechnology Corporation (Nasdaq: GNBT) today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product. These early results suggest that, should the current trend be maintained through the early 2011 completion date of the treatment phase of all enrolled subjects, the use of Generex Oral-lyn™ will support a non-inferiority claim relative to the standard-of-care injectable insulin. This position will be reviewed following a formal interim analysis after the 90-day results for all subjects become available.

It is gratifying for the Company to see a continuum of positive trends. Initial trending outcomes revealed that insulin resistance was not observed for subjects using Generex Oral-lyn™ and that subjects using Generex Oral-lyn™ demonstrated, on average, no weight gain and an actual decrease in Body Mass Index (BMI). This compared favorably to subjects using injectable insulin that have, on average, gained weight and experienced an increase in BMI. In addition, it was previously reported that when comparing hypoglycemic events, subjects using Generex Oral-lyn™ were observed to have a better Adverse Event profile than subjects using injectable insulin. These previous findings along with current trends of non-inferiority using recently collected information and extrapolations clearly positions this study favorably.

"This latest study trend is exciting news for us," said Anna Gluskin, the Generex President & Chief Executive Officer. "The Phase III study is on track and we will look forward to further analyses as we near completion of the study."

Market Moving News and Intelligence - Free Sign-Up http://www.streetinsider.com/premium_content.php"


Suponho que isto sejam excelentes noticias visto ela estar a subir +0.043 (12.68%)....

Obrigado

esta PR não diz nada de especial..... de uma forma geral a informação que nela consta já foi anteriormente divulgada pela generex. A generex espera terminar em Dezembro (mais mês, menos mês)a fase III do oral lyn para depois submeter os resultados à FDA, à EMEA e quem sabe à DCGI.

Cumprimentos

[pedro200]

Quem não arrisca não petisca!!! Mas realmente quem quer correr o risco de ficar de fora numa forte subida, que não considero que esta seja uma grande subida na Generex, já assisti a dias de subidas de 80% e mais, pode apanhar uns centimos mais a baixo........................

Não esquecer que hoje é dia da "Anual Meeting of Shareholders"

Vamos ver o que sai dai.....


Abraços

deve sair a aprovação do reserve split (3 para 1 é a minha aposta). Mas isso não significa que esse reserve split seja realmente efectuado... basta ler a carta que a gnbt recebeu do nasdaq.... a generex está apenas a cumprir uma das condições solicitadas....

[pedro200]

Boa tarde,

Hoje a gnbt está a subir ligeiramente...

Aguardo com interesse as próximas semanas, tendo conta o vasto pipeline da generex....

Cumprimentos

[Shevet]

Quem não arrisca não petisca!!! Mas realmente quem quer correr o risco de ficar de fora numa forte subida, que não considero que esta seja uma grande subida na Generex, já assisti a dias de subidas de 80% e mais, pode apanhar uns centimos mais a baixo........................

Não esquecer que hoje é dia da "Anual Meeting of Shareholders"

Vamos ver o que sai dai.....


Abraços

[pvg80713]

e eu ..... acabo de sair ! a 0,38 !

GNBT hoje a subir 14% !

[Peftoulas]

"July 28, 2010 9:35 AM EDT

Generex Biotechnology Corporation (Nasdaq: GNBT) today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product. These early results suggest that, should the current trend be maintained through the early 2011 completion date of the treatment phase of all enrolled subjects, the use of Generex Oral-lyn™ will support a non-inferiority claim relative to the standard-of-care injectable insulin. This position will be reviewed following a formal interim analysis after the 90-day results for all subjects become available.

It is gratifying for the Company to see a continuum of positive trends. Initial trending outcomes revealed that insulin resistance was not observed for subjects using Generex Oral-lyn™ and that subjects using Generex Oral-lyn™ demonstrated, on average, no weight gain and an actual decrease in Body Mass Index (BMI). This compared favorably to subjects using injectable insulin that have, on average, gained weight and experienced an increase in BMI. In addition, it was previously reported that when comparing hypoglycemic events, subjects using Generex Oral-lyn™ were observed to have a better Adverse Event profile than subjects using injectable insulin. These previous findings along with current trends of non-inferiority using recently collected information and extrapolations clearly positions this study favorably.

"This latest study trend is exciting news for us," said Anna Gluskin, the Generex President & Chief Executive Officer. "The Phase III study is on track and we will look forward to further analyses as we near completion of the study."

Market Moving News and Intelligence - Free Sign-Up http://www.streetinsider.com/premium_content.php"


Suponho que isto sejam excelentes noticias visto ela estar a subir +0.043 (12.68%)....

Fogo de vista ou vai disparar (finalmente) por aí acima?....agradecem-se opiniões...

Ps: estou dentro a 0,33€...

Obrigado

[MVP]

E aos poucos lá vão descendo.. Hoje (-2.35%)